S100A8 and gastric cancer: In summary, this work uses a CagA based in vitro screen which identified CEACAM6 as a novel biomarker of early gastric cancer and dysplastic lesions, and demonstrated the ability of a commercial endoscopy system to detect fluorescently labelled CEACAM6 reagent in ex vivo preparations of gastric cancer.